High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, January 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 5 tweeters

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 23 Mendeley

Summary Twitter Dimensions citations

So far, Altmetric has seen 5 tweets from 5 users, with an upper bound of 15,748 followers.

High efficacy and safety of CD38 and BCMA bispecific #CAR-T in relapsed or refractory multiple myeloma https://t.co/eqYO82T49S #CART #bmtsm #CARTcell #immunotherapy #tcellrx #CARTcells #CellTherapy

07 Jan 2022

Reply Retweet Favourite

RT @celltherapynews: ⚕️ A clinical study conducted at the Second Affiliated Hospital of Yangtze University demonstrated the efficacy and sa…

05 Jan 2022

Reply Retweet Favourite

RT @celltherapynews: ⚕️ A clinical study conducted at the Second Affiliated Hospital of Yangtze University demonstrated the efficacy and sa…

05 Jan 2022

Reply Retweet Favourite

⚕️ A clinical study conducted at the Second Affiliated Hospital of Yangtze University demonstrated the efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory #MultipleMyeloma. https://t.co/PqwRpawjrx https://t.co/IRYMpcBebH

05 Jan 2022

Reply Retweet Favourite

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 1 additional tweets.